Company intelligence / Profile preview
APEPTICO
Vienna, Vienna, Austria
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase 1 trial for AP301. Phase 2a clinical study of AP301-peptide delivered top-line results in the treatment of primary graft dysfunction in patients following lung transplantation. Received orphan drug designation for AP301 for treatment of primary graft dysfunction following lung transplantation and high altitude pulmonary oedema.
- Therapeutic areas
- PulmonologyEndocrinologyInfectious Diseases
- Modalities
- Peptide-based drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on APEPTICO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APEPTICO.